碳酸镧对维持性血液透析患者高磷血症的疗效及安全性Therapeutic effect and safety of lanthanum carbonate on hyperphosphatemia in maintenance hemodialysis patients
邓菲;冯静;李怡;马跃先;贺欣;王蔚;何强;王莉;
摘要(Abstract)：
目的探讨碳酸镧对维持性血液透析患者高磷血症治疗的有效性和安全性。方法采用多中心、队列研究方式,选择符合纳入标准的维持性血透患者60例,将其分为2组,每组30例,分别使用碳酸镧或醋酸钙进行降磷治疗,观察时间为8周,定期检测各项血生化指标,记录不良反应。结果治疗前,两组透析患者血磷、血钙水平比较差异无统计学意义(P>0.05),治疗结束时,两组血磷水平均降低(P<0.05)。但治疗后2、4、8周,碳酸镧组血磷水平均低于醋酸钙组(P<0.05),血磷水平达标率(<1.78 mmol/L)高于醋酸钙组(P<0.05)。治疗结束时,碳酸镧组血钙水平与治疗前比较差异无统计学意义(P>0.05),而醋酸钙组血钙水平升高(P<0.05)。碳酸镧组的各期发生高钙血症比率及累计不良反应发生率均低于醋酸钙组(P<0.05)。结论相较于常用含钙磷结合剂醋酸钙,碳酸镧对于维持性血液透析患者具有更好的降磷效果,且高钙血症的发生率降低,可避免增加血管钙化的风险,且不增加患者的不良反应。
关键词(KeyWords)： 维持性血液透析;高磷血症;碳酸镧;醋酸钙
基金项目(Foundation): 国家自然科学基金面上项目(81270828);; 四川省卫生与计划生育委员会科研课题(130206)
作者(Author): 邓菲;冯静;李怡;马跃先;贺欣;王蔚;何强;王莉;
Email:
DOI: 10.14053/j.cnki.ppcr.201704009
参考文献(References)：
- [1]Rhee CM,You AS,Koontz Parsons T,et al.Effect of highprotein meals during hemodialysis combined w ith lanthanum carbonate in hypoalbuminemic dialysis patients:findings from the Fr EDI randomized controlled trial[J].Nephrol Dial Transplant,2016 Sep 22.[Epub ahead of print]
- [2]Block GA,Klassen PS,Lazarus JM,et al.Mineral metabolism,mortality,and morbidity in maintenance hemodialysis[J].J Am Soc Nephrol,2004,15(8):2208-2218.
- [3]Zhang L,Wang F,Wang L,et al.Prevalence of chronic kidney disease in China:a cross-sectional survey[J].Lancet,2012,379(9818):722-815.
- [4]Schulman G,Himmelfarb J.Hemodialysis[A].In:Brenner,Rector.The Kidney[M].7th ed.Philadelphia:Saunders,2004:2563-2567.
- [5]Wojcicki JM.Hyperphosphatemia is associated with anemia in adults w ithout chronic kidney disease:results from the National Health and Nutrition Examination Survey(NHANES):2005-2010[J].BM C Nephrol,2013,14:178.
- [6]Adeney KL,Siscovick DS,Ix JH,et al.Association of serum phosphate w ith vascular and valvular calcification in moderate CKD[J].J Am Soc Nephrol,2009,20(2):381-387.
- [7]Voormolen N,Noordzij M,Grootendorst DC,et al.High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients[J].Nephrol Dial Transplant,2007,22(10):2909-2916.
- [8]Jean G,Chazot C.The French clinician's guide to the Kidney disease:Improving global outcomes(KDIGO)for chronic kidney disease-mineral and bone disorders(CKD-M BD)[J].Nephrol Ther,2010,6(3):151-157.
- [9]Andreoli SP,Bergstein JM,Sherrard DJ.Aluminum intoxication from aluminum-containing phosphate binders in children w ith azotemia not undergoing dialysis[J].N Engl J M ed,1984,310(17):1079-1084.
- [10]Sheikh MS,Maguire JA,Emmett M,et al.Reduction of dietary phosphorus absorption by phosphorus binders:a theoretical,in vitro and in vivo study[J].J Clin Invest,1989,83(1):66-73.
- [11]Hutchison AJ.Improving phosphate-binder therapy as a way forw ard[J].Nephrol Dial Transplant,2004,19(Suppl 1):i19-i24.
- [12]Keith M,De Sequera P,Clair F,et al.Lanthanum carbonate oral pow der:satisfaction,preference and adherence in French and Spanish patients w ith end-stage renal disease[J].Drugs Context,2016,5:212300.
- [13]Sprague SM,Ross EA,Nath SD,et al.Lanthanum carbonate vs.sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients:a crossover study[J].Clin Nephrol,2009,72(4):252-258.
- [14]Daugirdas JT,Finn WF,Emmett M,et al.The phosphate binder equivalent dose[J].Semin Dial,2011,24(1):41-49.
- [15]Altmann P,Barnett ME,Finn WF.Cognitive function in Stage5 chronic kidney disease patients on hemodialysis:no adverse effects of lanthanum carbonate compared w ith standard phosphate-binder therapy[J].Kidney Int,2007,71(3):252-259.
- [16]Wilson R,Zhang P,Smyth M,et al.Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy[J].Curr M ed Res Opin,2009,25(12):3021-3028.